Beyond COVID-19 and lessons learned in the United States

Transfusion Medicine

Volumn 33, Issue 1, 2023, Pages 6-15

  Gammon, Richard ^a   Katz, Louis M ^b   Strauss, Donna ^c   Rowe, Kathleen ^d   Menitove, Jay ^e   Benjamin, Richard J ^d   Goel, Ruchika ^b   Borge, Dayand ^f   Reichenberg, Stefan ^g   Smith, Roxane ^h  

^a OneBlood Inc   (United States)

^b ImpactLife Blood Services and Scott Co Health Department   (United States)

^c NEW YORK BLOOD CENTER   (United States)

^d CERUS CORPORATION   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g MacoPharma International GmbH   (Germany)

^h Macopharma USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SARS-COV-2 CONVALESCENT PLASMA;

BLOOD DONOR; CLINICIAN; CORONAVIRUS DISEASE 2019; COVID-19 CONVALESCENT PLASMA TREATMENT; FOOD AND DRUG ADMINISTRATION; FUTUROLOGY; HOSPITAL; HUMAN; LEARNING; MEDICAL RESOURCE SHORTAGE; NONHUMAN; PANDEMIC; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED STATES; VIRUS STRAIN; WIDESPREAD COMMUNITY TRANSMISSION; PASSIVE IMMUNIZATION;

BLOOD DONORS; COVID-19; COVID-19 SEROTHERAPY; HUMANS; IMMUNIZATION, PASSIVE; PANDEMICS; SARS-COV-2; UNITED STATES;

EID: 85135247952     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/tme.12896     Document Type: Review

References (46)

1. Mulcahy AW, Kapinos KA, Briscombe B, et al. Toward A Sustainable Blood Supply In The United States: An Analysis Of The Current System And Alternatives For The Future. The Rand Corporation; 2016. https://www.rand.org/content/dam/rand/pubs/research_reports/RR1500/RR1575/RAND_RR1575.pdf
2. Klein HG, Hrouda JC, Epstein JS. Crisis in the sustainability of the US blood system. 2017. N Engl J Med. 2017;377(15):1485-1488.
3. Coordinating the nation's blood supply during disasters and biological events. V 2.0. Disaster Operations Handbook. AABB; 2008. https://www.aabb.org/docs/default-source/default-document-library/about/disaster-operations-handbook.pdf?sfvrsn=619c092c_0
4. AABB disaster response. 2022. https://www.aabb.org/about-aabb/organization/disaster-response#:~:text=The%20AABB%20Interorganizational%20Task%20Force,messages%20to%20the%20public%20regarding
5. Carey PM, High PM, Schlumpf KS, et al. Donation return time at fixed and mobile donation sites. Transfusion. 2012;52:127-133.
6. Surgeon general urges young people to donate blood to help hospitals during coronavirus pandemic; 2022. https://www.washingtonexaminer.com/news/surgeon-general-urges-young-people-to-donate-blood-to-help-hospitals-during-coronavirus-pandemic
7. Gammon RR, Prichard AB, Gannett MS, Yordanov B. The effect of COVID-19 on blood donation habits. Transfusion. 2021;61:1134-1140.
8. Hess A. Engaging “disaster” donors. SCABB annual meeting presentation; 2020.
9. Vassallo RR, Bravo MD, Kamel H. Pandemic blood donor demographics–do changes impact blood safety. Transfusion. 2021;61:1389-1393. doi:10.1111/trf.16320
10. American red cross faces sever blood shortages as coronavirus outbreak threatens availability of nation's supply; 2022. https://www.redcross.org/about-us/news-and-events/press-release/2020/american-red-cross-faces-severe-blood-shortage-as-coronavirus-outbreak-threatens-availability-of-nations-supply.html
11. Gammon RR, Counts K, Gannett M, et al. Data science optimized inventory and minimized wastage during a pandemic. Vox Sang. 2020;115(S1):104. doi:10.1111/vox.13031
12. Kracalik I, Mowla S, Katz L, Cumming M, Sapiano MRP, Basavaraju SV. Impact of the early coronavirus disease 2019 pandemic on blood utilization in the United States: a time-series analysis of data reported to the National Healthcare Safety Network Hemovigilance Module. Transfusion. 2021;61:S36-S43.
13. Reik R, Gammon RR, Carol N, et al. Rapid development of a De novo convalescent plasma program in response to a global pandemic: a large southeastern U.S. blood Center's experience. J Clin Apher. 2021;36:533-546. doi:10.1002/jca.21889
14. China puts 245 COVID-19 patients on convalescent plasma therapy; 2022. http://www.xinhuanet.com/english/2020-02/28/c_138828177.htm
15. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582-1589. doi:10.1001/jama.2020.4783
16. Investigational COVID-19 Convalescent Plasma. FDA Guidance for Industry. March 2020 (Updated January 7, 2022); 2022. https://www.fda.gov/media/136798/download
17. Convalescent Plasma EUA letter of authorization. August 23, 2020 (Updated December 28, 2021); 2022. https://www.fda.gov/media/141477/download
18. Katz LM. A little clarity on convalescent plasma for COVID-19. N Engl J Med 2021;384:666-668. doi:10.1056/NEJMe2035678
19. Writing Committee for the REMAP-CAP Investigators. Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2021;326(17):1690-1702. doi:10.1001/jama.2021.18178
20. Libster R, Pérez Marc G, Wappner D, et al. Early High-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610-618.
21. Horby PW, Estcoure L, Peto L, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021. doi:10.1101/2021.03.09.21252736
22. Bégin P, Callum J, Heddle NM, et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials. 2021;22(1):323.
23. Prasad M, Seth T, Elavarasi A. Efficacy and safety of convalescent plasma for COVID-19: a systematic review and meta-analysis. Indian J Hematol Blood Transfus. 2021;37:1-19.
24. Tortosa F, Carrasco G, Ragusa M, et al. Use of convalescent plasma in patients with coronavirus disease (Covid-19): systematic review and meta-analysis. medRxiv. 2021. doi:10.1101/2021.02.14.20246454
25. Sun M, Xu Y, He H, et al. A potentially effective treatment for COVID-19: a systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. Int J Infect Dis. 2020;98:334-346.
26. Devasenapathy N, Ye Z, Loeb M, et al. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis. CMAJ. 2020;192:E745-E755.
27. Vegivinti CTR, Pederson JM, Saravu K, et al. Efficacy of convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Clin Apher. 2021;36:470-482. doi:10.1002/jca.21881
28. Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment with Clinical Outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021;325(12):1185-1195. doi:10.1001/jama.2021.2747
29. Balcells ME, Rojas L, le Corre N, et al. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial. PLoS Med. 2021;18(3):e1003415. doi:10.1371/journal.pmed.1003415
30. Sullivan DJ, Gebo KA, Shoham S, et al. Early outpatient treatment for Covid-19 with convalescent plasma. N Engl J Med. 2022;386:1700-1711. doi:10.1056/NEJMoa2119657
31. Focosi J, Franchini M, Pirofski L. COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes. CMR. 2022;27:e0020021.
32. Bauchner H, Fontanarosa PM. Randomized clinical trials and COVID-19: managing expectations. JAMA. 2020;323(22):2262-2263.
33. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460-470.
34. Rasheed AM, Fatak DF, Hashim HA, et al. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad. Iraq Infez Med. 2020;28(3):357-366.
35. Schmitz AJ, Turner JS, Liu Z, et al. A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants. BioRxiv. 2021. doi:10.1101/2021.03.24.436864
36. Stamatatos L, Czartoski WY, Wan Y-H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372:1413-1418. doi:10.1126/science.abg9175
37. Petkova E, Antman EM, Troxel AB. Pooling data from individual clinical trials in the COVID-19 era. JAMA. 2020;324(6):543-545. doi:10.1001/jama.2020.13042
38. al-Riyami AZ, Burnouf T, Wood EM, et al. International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemic. Vox Sang. 2022;117:1-9.
39. Coronavirus (COVID-19) update: FDA provides updated guidance to address the urgent need for blood during the pandemic; 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-updated-guidance-address-urgent-need-blood-during-pandemic
40. Blood establishment computer system validation in the user's facility. FDA guidance for industry; 2013. https://www.fda.gov/media/72533/download
41. Ocampo, T. FDA revises blood donation deferral guidelines amid COVID-19; lifts limits for LGBTQ donors; 2022. https://www.ibtimes.com/fda-revises-blood-donation-deferral-guidelines-amid-covid-19-lifts-limits-lgbtq-2964640
42. US health and human services report to congress of the adequacy of the national blood supply; 2020. https://www.aabb.org/docs/default-source/default-document-library/positions/hhs-report-to-congress-on-the-adequacy-of-the-national-blood-supply.pdf?sfvrsn=aeea20ff_4
43. Holmberg M, Lundgren B. Framing post-pandemic preparedness: comparing eight European plans; 2022. https://www.researchgate.net/publication/297598673_Framing_post-pandemic_preparedness_Comparing_eight_European_plans
44. Casadevall A., Paneth N. A little debate on plasma is healthy for science; 2022. https://www.wsj.com/articles/a-little-debate-on-plasma-is-healthy-for-science-11600790067
45. RescEU: Factsheet; 2022. https://ec.europa.eu/echo/what/civil-protection/resceu_en
46. European civil protection and humanitarian aid operations - Emegerency response coordination centre (ERCC); 2022. https://erccportal.jrc.ec.europa.eu/